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Recent evidence suggests that corticotropin-releasing factor (CRF) receptor (CRFR) signaling is involved in modulating binge-like ethanol
consumption in C57BL/6J mice. In this report, a series of experiments were performed to further characterize the role of CRFR signaling
in binge-like ethanol consumption. The role of central CRFR signaling was assessed with intracerebroventricular (i.c.v.) infusion of the
nonselective CRFR antagonist, a-helical CRF9–41 (0, 1, 5, 10 mg/1ml). The contribution of central CRF type 2 receptor (CRF2R) signaling
was assessed with i.c.v. infusion of the selective CRF2R agonist, urocortin (Ucn) 3 (0, 0.05, 0.1, or 0.5mg/1 ml). The role of the
hypothalamic–pituitary–adrenal (HPA) axis was assessed by pretreating mice with intraperitoneal (i.p.) injection of (1) the corticosterone
synthesis inhibitor, metyrapone (0, 50, 100, 150 mg/kg) or (2) the glucocorticoid receptor antagonist, mifepristone (0, 25, 50 mg/kg), and
(3) by using radioimmunoassay to determine whether binge-like ethanol intake influenced plasma corticosterone levels. Finally, we
determined whether the ability of the CRF1R antagonist, CP-154,526 (CP; 0, 10, 15 mg/kg, i.p.), to blunt binge-like drinking required
normal HPA axis signaling by comparing the effectiveness of CP in adrenalectomized (ADX) and normal mice. Results showed that i.c.v.
infusion of a 1 mg dose of a-helical CRF9–41 significantly attenuated binge-like ethanol consumption relative to vehicle treatment, and i.c.v.
infusion of Ucn 3 dose-dependently blunted binge-like drinking. On the other hand, metyrapone nonselectively reduced both ethanol
and sucrose consumption, mifepristone did not alter ethanol drinking, and binge-like drinking did not correlate with plasma
corticosterone levels. Finally, i.p. injection of CP significantly attenuated binge-like ethanol intake in both ADX and normal mice. Together,
these results suggest that binge-like ethanol intake in C57BL/6J mice is modulated by CRF1R and CRF2R signaling, such that blockade of
CRF1R or activation of CRF2R effectively reduces excessive ethanol intake. Furthermore, normal HPA axis signaling is not necessary to
achieve binge-like drinking behavior.
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Binge drinking, a common term used to define excessive
alcohol intake over a short period of time, has become a
serious concern in the United States and worldwide
(Centers for Disease Control and Prevention (CDC), 2009).
Binge drinking has been implicated in numerous health
problems including heart disease, high blood pressure, and
type 2 diabetes (Sundell et al, 2008; Toriola et al, 2009), and
increases the proclivity to engage in other risky behaviors
(Jonas et al, 2000; Ling et al, 2009; Nelson et al, 2009).
Although binge drinking consistently ranks among the top
adolescent risk behaviors (Eaton et al, 2008), emerging
research indicates that a significant proportion of the adult
population also engages in this behavior (Nelson et al,
2009). The potential societal impact of binge drinking is
significant, as this pattern of ethanol consumption is
believed to contribute to the development of ethanol
dependence (Bonomo et al, 2004; Jennison, 2004; Keyes
et al, 2008; Koob, 2000).
The ‘drinking in the dark’ (DID) procedure is an animal
model of human binge drinking and has been used to
identify neurochemical modulators of binge-like ethanol
consumption (Koob, 2000; Rhodes et al, 2005, 2007; Sparta
et al, 2008; Szumlinski et al, 2007). The DID procedure
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reliably generates high levels of voluntary ethanol con-
sumption and corresponding blood–ethanol concentrations
(BECs) over relatively short periods of time by providing
ethanol-preferring C57BL/6J mice limited access to 20%
ethanol solution beginning 3-h into the dark portion of
the animals’ light cycle (Rhodes et al, 2005). With
DID procedures, animals typically achieve BECs above
80–100 mg per 100 ml over a 2–4 h period (Lyons et al, 2008;
Rhodes et al, 2005, 2007). The BEC levels that are achieved
in a short period of time are within ranges recently
proposed in defining features of human binge drinking
(National Institute on Alcohol and Alcoholism Advisory
Council 2004; Courtney and Polich, 2009), suggesting that
the DID procedure models important aspects of human
binge drinking behavior. Importantly, C57BL/6J mice
exhibit behavioral intoxication with DID procedures as
measured by deficits in motor behavior in rotarod and
balance beam tests (Rhodes et al, 2007). To date,
dopaminergic (Kamdar et al, 2007), opioidergic (Kamdar
et al, 2007), acetylcholinergic (Hendrickson et al, 2009), and
glutamatergic (Gupta et al, 2008) signaling have been
implicated in binge-like ethanol consumption using the
DID paradigm.
Corticotropin-releasing factor (CRF) and the urocortin
(Ucn) peptides (Ucn1, Ucn2, and Ucn3) have been
implicated in the modulation of multiple neurobiological
systems, including those that regulate feeding, anxiety and
depression, hypothalamic–pituitary–adrenal (HPA) axis
signaling, and ethanol consumption (Arborelius et al,
1999; Hauger et al, 2006; Heilig and Koob, 2007; Heinrichs
and Richard, 1999; Kehne, 2007; Kuperman and Chen, 2008;
Menzaghi et al, 1994; Ryabinin and Weitemier, 2006; Smith
and Vale, 2006). CRF and the Ucn peptides produce their
effects by binding to the G-protein-coupled CRF type 1
(CRF1R) and CRF type 2 (CRF2R) receptors. CRF binds to
both receptors, but has greater affinity to the CRF1R
(Hauger et al, 2006; Pioszak et al, 2008; Ryabinin et al,
2002). Although Ucn1 binds with equal affinity to both
CRF1R and CRF2R, Ucn2 and Ucn3 are CRF2R agonists
(Hauger et al, 2006; Pioszak et al, 2008; Ryabinin et al,
2002). CRF and the Ucn peptides are expressed ubiquitously
throughout the brain, each with unique but overlapping
expression profiles (Hauger et al, 2006; Imaki et al, 1996;
Potter et al, 1994; Ryabinin et al, 2002). CRF and the Ucn
peptides exert their behavioral and neuroendocrine actions
through central hypothalamic and extrahypothalamic path-
ways (Hauger et al, 2006; Heilig and Koob, 2007; Heinrichs
and Koob, 2004; Kehne, 2007; Koob and Le Moal, 2008;
Ryabinin et al, 2002).
Recent evidence suggests that CRF receptor (CRFR)
signaling modulates binge-like ethanol consumption
(Sparta et al, 2008). Thus, pretreatment with intraperitoneal
(i.p.) injection of a peripherally bioavailable CRF1R
antagonist, CP-154,526 (CP), attenuated excessive ethanol
consumption in binge-like drinking C57BL/6J mice that
achieved BECs of B80 mg per 100 ml, but failed to alter
ethanol consumption by mice that drank moderate amounts
of ethanol and achieved low BECs (B40 mg per 100 ml or
less). Furthermore, pretreatment with CP did not affect
sucrose consumption, suggesting that CRF1R activity is
selectively recruited by high levels of ethanol consumption
(ie, those resulting in BECs greater than 80 mg per 100 ml).
However, the mechanism by which CRFR signaling
modulates binge-like ethanol drinking has not been
investigated. Here, we show that the effects of CRFR
antagonism on binge-like drinking are centrally mediated,
and that activation of the CRF2R protects against binge-like
ethanol intake. As ethanol exposure causes activation of the
HPA axis through CRFR signaling and because HPA axis
activity has been shown to modulate ethanol consumption
in rodents (Krishnan et al, 1991; Morrow et al, 2006), we
determined whether normal HPA axis signaling is necessary
for the expression of binge-like ethanol drinking. We show
that normal HPA axis activity is not necessary, and that
CRF1R antagonist-induced reduction of binge-like drinking
does not involve HPA axis signaling. These observations
provide novel insight into the mechanism by which CRFR
signaling modulates binge-like drinking behavior in C57BL/
6J mice, and expand the literature by showing that CRF1R
and CRF2R signaling are recruited during the early phases
of excessive ethanol ingestion.
MATERIALS AND METHODS
Animals
Male C57BL/6J mice (n¼ 191; Jackson Laboratories, Jackson,
MS) were 6–8 weeks of age and weighed 18–26 g on arrival,
and male C57BL/6J mice that underwent adrenalectomy
(ADX; n¼ 24; Jackson Laboratories, Bar Harbor, ME) or
sham surgery (SHAM; n¼ 40; Jackson Laboratories, Bar
Harbor, ME) were 8–10 weeks of age and weighed 15–26 g
on arrival. As per instructions provided by Jackson
Laboratories, ADX (and SHAM) mice were given access to
a 0.9% saline solution for the first 4 days after arrival to help
maintain sodium chloride balance. Mice were individually
housed in plastic cages, were allowed to habituate to their
environment for at least 1 week before the start of the
experiments, and had ad libitum access to standard rodent
chow and water except where noted. The colony room was
maintained at approximately 221C with a 12 h light/12 h
dark cycle and lights went off at 1000 hours. All procedures
used are in accordance with the National Institute of Health
guidelines, and were approved by the University of North
Carolina Institutional Animal Care and Use Committee.
Drugs
Ethanol (20% v/v) solutions were prepared using tap water
and 100% ethyl alcohol (Decon Laboratories Inc., King of
Prussia, PA) and sucrose (w/v) solutions were prepared
using tap water and D-sucrose (Fisher Scientific, Fair Lawn,
NJ). The nonselective CRF receptor antagonist, a-helical
CRF9–41 (a-helical CRF; Sigma-Aldrich, Saint Louis, MO),
was dissolved in sterile water and injected intracerebroven-
tricularly (i.c.v.; vehicle, 1, 5, or 10 mg/1ml) approximately
60 min before the start of behavioral testing. Doses and the
time course were based on previous studies (Brauns et al,
2001; Nishikawa et al, 2004). In addition, a-helical CRF
effectively blocks CRF-induced ACTH secretion in vitro and
in vivo (Rivier et al, 1984), and attenuates CRF-induced
adenylate cyclase activity (Battaglia et al, 1987). The
selective CRF2R agonist, Ucn3 (Phoenix Pharmaceuticals
Inc., Burlingame, CA), was dissolved in sterile water and
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injected i.c.v. (vehicle, 0.05, 0.1, or 0.5 mg/1 ml) approxi-
mately 90 min before the start of behavioral testing. Doses
and the time course were extrapolated from previous
research (D’Anna et al, 2005; Valdez and Koob, 2004;
Venihaki et al, 2004). Ucn3 is a highly selective agonist for
CRF2R (Ki¼ 9.1 nM) vs CRF1R (Ki410 000 nM) (Hauger
et al, 2006; Ryabinin et al, 2002). The corticosterone
synthesis inhibitor, 2-Methyl-1,2-di-3-pyridyl-1-propanone
(metyrapone; Sigma-Aldrich) was suspended in 0.5%
carboxymethylcellulose (CMC; Sigma-Aldrich) and injected
intraperitoneally (i.p; vehicle, 50, 100, or 150 mg/kg)
approximately 30 min before the start of behavioral testing.
The time course and dose range were based on previous
data (Nair and Bonneau, 2006; O’Callaghan et al, 2005).
Importantly, metyrapone has been shown to effectively
deplete circulating plasma corticosterone levels under basal
(Laborie et al, 1995, 1997) and stressed (Krugers et al, 2000)
conditions. The glucocorticoid receptor antagonist mife-
pristone (also called RU38486; Sigma-Aldrich) was sus-
pended in 0.5% CMC and dissolved by sonicating for
15 min, and was delivered i.p. (vehicle, 25, 50, or 100 mg/kg)
approximately 30 min before the start of behavioral testing.
Similar doses and time courses have been previously used
(Koenig and Olive, 2004; O’Callaghan et al, 2005; Roberts
et al, 1995). Mifepristone displays high binding affinity for
the glucocorticoid type I receptor (Ki¼ 0.4 nM), and
mifepristone and its active metabolites are known to cross
the blood–brain barrier (Heikinheimo et al, 1994; Peeters
et al, 2004). The selective CRF1R antagonist, CP-154,526
(butyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo
[2,3-d]pyrimidin-4-yl]-ethylamine) (CP; Pfizer, Groton,
CT), was suspended in 0.5% CMC and injected approxi-
mately 60 min before the start of behavioral testing, as
previously described (Sparta et al, 2008). This drug is
bioavailable, crosses the blood brain barrier, and is highly
selective for CRF1R (Ki¼ 2.1 nM) vs CRF2R (Ki410 mM)
(Chen et al, 1997; Keller et al, 2002; Schulz et al, 1996).
‘Drinking in the Dark’ Procedure
A 4-day DID procedure was used in all experiments (Rhodes
et al, 2005; Sparta et al, 2008). On days 1–3, beginning 2.5 h
into the dark cycle, water bottles were removed from all
cages. For all experiments involving i.p. drug administra-
tion, animals were weighed and injected with the appro-
priate volume (5 ml/kg) of the specified vehicle to habituate
them to injections. For all experiments involving i.c.v. drug
administration, animals were handled for 1 min/day on days
1–3. Beginning 3 h into the dark cycle, small ethanol bottles
(or water bottles, where specified) were weighed (to the
nearest 0.01 g) and placed on cages for 2 h (bottles were
again weighed after removal to calculate consumption). The
same schedule was followed on day 4, except that ethanol
access was extended to 4 h and immediately thereafter, and
tail blood samples were collected for analysis of BECs. For
all experiments involving drug administration, animals
were pretreated with the appropriate dose of drug before the
ethanol access period on day 4.
Surgery and Infusion Procedures
Approximately 2 weeks after arrival, mice underwent
surgery to implant cannulae aimed at the lateral ventricle.
Specifically, mice were anesthetized with a cocktail of
ketamine (117 mg/kg) and xylazine (7.92 mg/kg) and
surgically implanted with a 26-gauge cannula (Plastic One,
Roanoke, VA) aimed at the left lateral ventricle (0.2 mm
posterior to bregma, 1.0 mm lateral to the midline, and
2.3 mm ventral to the skull surface) (Navarro et al, 2005).
Mice were allowed to recover approximately 2 weeks before
experimental procedures were started. Cannula placement
was verified histologically at the end of the experiment. The
i.c.v. infusions were given manually in a 1.0 ml volume over
a 1-min period with a 1.0 ml Hamilton microsyringe. Mice
were familiarized to infusion procedures 2–3 times before
the i.c.v. experiments described below.
Blood–Ethanol Concentration
Approximately 10 ml of blood was collected from the tail
vein of each mouse immediately following ethanol access on
day 4 of the DID procedure to analyze for BEC. Samples
were centrifuged, and 5ml of plasma from each sample was
analyzed (Analox Instruments, Lunenburg, MA).
Experiment 1: Effects of i.c.v. Administration of
a-Helical CRF9–41 on Binge-Like Ethanol Consumption
Animals were assigned to groups equated for ethanol
consumption during the first 3 days of DID procedures.
On day 4, groups were given an i.c.v. infusion as described
above. An additional set of ethanol-naive mice was used to
assess the effects of a-helical CRF on consumption of a 10%
sucrose solution, a concentration that has been used
previously to assess the specificity of drug effects to ethanol
consumption (Sparta et al, 2008). Access to the sucrose
solution over 4 days followed the same DID procedures
used with ethanol solution.
Experiment 2: Effects of i.c.v. Administration of Ucn3 on
Binge-Like Ethanol Consumption
Animals were assigned to groups equated for ethanol
consumption during the first 3 days of DID procedures,
and on day 4 mice were given i.c.v. infusions as described
above. A subset of these animals was then used to assess the
effects of Ucn3 on consumption of a 10% sucrose solution
using DID procedures.
Experiments 3 and 4: Effects of Mifepristone and
Metyrapone on Binge-Like Ethanol Consumption
Mice were assigned to groups equated for ethanol
consumption during the first 3 days of DID procedures,
and on day 4 each group was given i.p. injection of
mifepristone or vehicle as described above. Approximately
2 weeks later, these animals underwent a second round of
DID procedures, as the mifepristone manipulation had no
effect on DID ethanol intake (see Results section below).
Mice were redistributed into groups equated for ethanol
consumption on days 1–3. On day 4, mice were given i.p.
injection of metyrapone or vehicle as described above. The
effects of metyrapone on 4 h consumption of a 10% sucrose
solution were assessed in an additional set of ethanol-naive
animals. As peak brain levels of mifepristone and its
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metabolites are achieved within 1–2 h and eliminated by 4 h
following peripheral administration (Heikinheimo et al,
1994), an additional set of ethanol-naive mice underwent
DID procedures as described above, except that ethanol
consumption was measured hourly throughout ethanol
access on day 4.
Experiment 5: The Effects of Binge-Like Ethanol
Consumption on Plasma Corticosterone Levels
Ethanol-naive mice were divided into two groups equated
for body weight on arrival. During the 4-day DID
procedure, one group was given access to a 20% ethanol
solution, whereas the second group received water.
Approximately 20 ml of blood was collected from the tail
vein of each mouse immediately following the 4 h session on
day 4 (7 h into the dark cycle). Samples were centrifuged,
and plasma was removed and frozen at 201C. Plasma
corticosterone levels were assessed using 10 ml of plasma
from each sample and a Radioimmuno Assay Kit (MP
Biomedicals, Solon, OH) (Salling et al, 2008).
Experiment 6: The Effects of CP and ADX on Binge-Like
Ethanol Consumption
ADX and SHAM mice were divided into groups equated for
ethanol consumption during the first 3 days of the
procedure and then given i.p. injections of vehicle or CP
on day 4 (vehicle, 10, or 15 mg/kg). Two days later, the
effects of adrenalectomy on 4 h consumption of a 3%
sucrose solution were assessed in these mice.
Statistical Analysis
For all experiments, the first 3 days of ethanol consumption
were analyzed using repeated measures analyses of variance
(ANOVAs), and the fourth day of ethanol (or sucrose)
consumption and BECs were assessed using ANOVAs.
When significant differences were observed, follow-up
Bonferroni post hoc analyses were performed. A repeated
measures ANOVA was performed to assess the hourly
effects of mifepristone (hour dose) over the 4 h test in
which the hourly measures were collected. The relationship
between day 4 ethanol consumption and BECs was assessed
with Pearson’s R correlations. In some cases, the amount of
blood sample collected for BEC analyses were not adequate,
and therefore were not included in the analyses. All data are
expressed as mean±SEM, and significance was accepted at the
po0.05 level (two-tailed) for ANOVA and Bonferroni tests.
RESULTS
Experiment 1: Effects of i.c.v. Administration of
a-helical CRF9–41 on Binge-Like Ethanol Consumption
Ethanol consumption. Ethanol consumption during the
first 3 days of DID did not differ on the basis of drug
treatment grouping (drug treatment: F(3, 30)¼ 1.06,
p¼ 0.380; see Table 1). As shown in Figure 1a, ethanol
consumption on the fourth day of the DID procedure was
significantly affected by drug treatment (drug treatment:
F(3, 31)¼ 3.183, p¼ 0.039), as were BECs (drug treatment:
F(3, 31)¼ 3.792, p¼ 0.021; see Figure 1b). Bonferroni post
hoc analyses reveal that animals pretreated with 1 mg of
a-helical CRF consumed significantly less ethanol than did
animals pretreated with vehicle and achieved significantly
lower BECs. BECs corresponded with ethanol consumption,
irrespective of a-helical CRF treatment (r¼ 0.80, po0.001).
Sucrose consumption. Consumption of a 10% sucrose
solution was not altered by pretreatment with 1 mg of
a-helical CRF, as confirmed by the results of a one-way
ANOVA (drug treatment: F(1, 19)¼ 2.749, p¼ 0.115; see
Figure 1c).
Experiment 2: Effects of i.c.v. Administration of Ucn3 on
Binge-Like Ethanol Consumption
Ethanol consumption. Ethanol consumption during the
first 3 days of consumption did not differ on the basis of
drug treatment grouping (drug treatment: F(3, 31)¼ 0.23,
p¼ 0.87; see Table 1). As shown in Figure 2a, ethanol
consumption on the fourth day of the DID procedure was
dose-dependently affected by drug treatment (drug treat-
ment: F(3, 30)¼ 6.963, p¼ 0.001), as were BECs (drug
treatment: F(3, 30)¼ 6.504, p¼ 0.002; see Figure 2b). Bon-
ferroni post hoc analyses revealed that animals pretreated
with 0.1 or 0.5 mg of Ucn3 consumed significantly less
ethanol than did animals pretreated with vehicle, and
animals pretreated with all doses achieved significantly
lower BECs. BECs corresponded with ethanol consumption,
irrespective of Ucn3 treatment (r¼ 0.85, po0.001).
Sucrose consumption. Consumption of a 10% sucrose
solution was not altered by pretreatment with either 0.1 or
0.5 mg Ucn3, as confirmed by the results of a one-way
ANOVA (drug treatment: F(2, 29)¼ 2.615, p¼ 0.092; see
Figure 2c).
Experiment 3: Effects of Mifepristone on Binge-Like
Ethanol Consumption
Ethanol consumption during the first 3 days of the DID
procedure did not differ on the basis of drug treatment
grouping (drug treatment: F(3, 36)¼ 0.005, p¼ 0.999; see
Table 1). As shown in Figure 3a, ethanol consumption on
the fourth day of the DID procedure was not altered by drug
Table 1 Mean (±SEM) Ethanol Consumption on Days 1–3 of the
DID Procedure
Experiment Mean ethanol consumption g/kg/2 h±SEM
Day 1 Day 2 Day 3
1: ICV a-helical CRF 2.42±0.18 4.02±0.19 3.52±0.21
2: ICV UCN3 2.65±0.14 3.11±0.17 3.88±0.19
3: MifepristoneF4 h 2.42±0.16 2.54±0.25 3.07±0.18
3: MifepristoneFhourly 3.66±0.24 3.39±0.21 3.28±0.24
4: Metyrapone 2.72±0.17 3.31±0.20 4.08±0.23
5: Corticosterone RIA 2.57±0.18 2.89±0.29 2.85±0.18
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treatment (drug treatment: F(3, 37)¼ 0.431, p¼ 0.732).
Likewise, hourly ethanol consumption on the fourth day
of the DID procedure was not altered by drug treatment
(drug treatment: F(2, 27)¼ 0.637, p¼ 0.536; see Figure 3b).
Ethanol consumption did differ by hour (hour:
F(31, 81)¼ 10.552, po0.001), though the interaction be-
tween drug treatment and hour was not significant (drug
treatment hour: F(6, 81)¼ 1.070, p¼ 0.387). BECs corre-
lated significantly with ethanol consumption (r¼ 0.74,
po0.001; data not shown), and were unaffected by drug
treatment (drug treatment: F(3, 37)¼ 0.220, p¼ 0.882; data
not shown).
Experiment 4: Effects of Metyrapone on Binge-Like
Ethanol Consumption
Ethanol consumption. Ethanol consumption during the
first 3 days of the DID procedure did not differ on the basis
of drug treatment grouping (drug treatment:
F(3, 32)¼ 0.922, p¼ 0.922; see Table 1). As shown in
Figure 3c, ethanol consumption on day 4 was significantly
and dose-dependently altered by drug treatment (drug
treatment: F(3, 35)¼ 16.468, po0.001), as were BECs (drug
Figure 1 The effects of a-helical CRF on (a) mean 4-h 20% ethanol
consumption and (b) blood–ethanol concentrations (n¼ 5–10 per group).
(c) Effects of a-helical CRF on mean 4-h 10% sucrose consumption in
C57BL/6J animals (n¼ 10 per group). Data represent mean±SEM, and are
normalized for body weight. *po0.05 vs vehicle-treated group determined
by Bonferroni post hoc analyses.
Figure 2 The effects of Ucn3 on (a) mean 4-h 20% ethanol
consumption (b) and blood–ethanol concentrations (n¼ 6–8 per group).
(c) Effects of Ucn3 on mean 4-h 10% sucrose consumption in C57BL/6J
animals (n¼ 10 per group). Data represent mean±SEM, and are
normalized for body weight. *po0.05 vs vehicle-treated group determined
by Bonferroni post hoc analyses.
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treatment: F(3, 34)¼ 11.200, po0.001; data not shown).
Bonferroni post hoc analyses reveal that animals pretreated
with 100 mg/kg or 150 mg/kg of metyrapone consumed
significantly less ethanol than did animals pretreated with
vehicle, and achieved significantly lower BECs (data not
shown). BECs corresponded with the dose-dependent
attenuation of ethanol consumption by metyrapone
(r¼ 0.74, po0.001).
Sucrose consumption. Consumption of a 10% sucrose
solution was significantly altered by pretreatment with
metyrapone, as confirmed by the results of a one-way
ANOVA (drug treatment: F(2, 22)¼ 13.055, po0.001; see
Figure 3d). Bonferroni post hoc analyses reveal that animals
pretreated with 100 or 150 mg/kg consumed significantly
less of the 10% sucrose solution than did animals pretreated
with vehicle.
Experiment 5: The Effects of Binge-Like Ethanol
Consumption on Plasma Corticosterone Levels
As shown in Figure 3e, plasma corticosterone levels were
not significantly altered by ethanol consumption compared
with water consumption after 4 h of ethanol access
(F(1, 29)¼ 0.202, p¼ 0.657). Plasma corticosterone levels
were not significantly correlated to ethanol consumption
(r¼0.12, p¼ 0.330; see Figure 3f).
Experiment 6: The Effects of CP and ADX on Binge-Like
Ethanol Consumption
A repeated measures ANOVA was performed on body
weight data over the 4 days of DID procedures to determine
whether ADX had a negative impact on the health of mice.
Relative to SHAM-treated mice (22.73±0.27 g), ADX mice
(22.24±0.35 g) did not show altered body weight over the
4-day procedure, suggesting that ADX mice remained
healthy over the course of the experiment.
Ethanol consumption. The results of a repeated measures
ANOVA reveal a significant main effect of surgery on
ethanol consumption during the first 3 days of the DID
procedure (surgery condition: F(1, 58)¼ 9.995, p¼ 0.002;
see Figure 4a), but no effect based on drug treatment
grouping (F(2, 58)¼ 0.027, p¼ 0.973; data not shown). As
shown in Figure 4b, pretreatment with CP significantly
altered ethanol consumption by both ADX and SHAM
animals on day 4 (drug treatment: F(2, 58)¼ 13.827,
po0.001). The main effects of surgery and the interaction
between surgery condition and drug treatment were not
significant on day 4 (surgery condition: F(1, 58)¼ 3.090,
p¼ 0.084; surgery condition drug treatment:
F(2, 28)¼ 1.332, p¼ 0.272). Bonferroni post hoc analyses
reveal that pretreatment with either the 10 or 15 mg/kg dose
of CP significantly attenuated ethanol consumption relative
to vehicle treatment in both ADX and SHAM animals.
Blood–ethanol concentrations. Results indicated a signifi-
cant main effect of surgery (surgery condition:
F(1, 58)¼ 6.323, p¼ 0.015), in addition to a significant main
effect of drug (drug treatment: F(2, 58)¼ 8.724, po0.001),
on BECs achieved on day 4 of the DID procedure. The
interaction between these two factors was not significant
(surgery condition drug treatment: F(2, 58)¼ 0.045,
p¼ 0.956). Bonferroni post hoc analyses reveal that ADX
animals achieved lower BECs relative to SHAM animals (see
Figure 4c). In agreement with the ethanol consumption
data, Bonferroni post hoc analyses also reveal that pretreat-
ment with either the 10 or 15 mg/kg doses of CP
significantly attenuated BECs in both ADX and SHAM
animals.
Sucrose consumption. Consumption of a 3% sucrose
solution was significantly attenuated in ADX animals
relative to SHAM animals (surgery condition:
F(1, 62)¼ 12.153, p¼ 0.001; see Figure 4d).
Figure 3 Effects of mifepristone on (a) mean 4-h 20% ethanol consumption (n¼ 8–10 per group), and (b) mean hourly 20% ethanol consumption
(n¼ 10 per group). The effects of metyrapone on (c) mean 4-h 20% ethanol consumption (n¼ 9 per group), and (d) mean 4-h 10% sucrose consumption
(n¼ 7–8 per group). (e) Effects of 4-h 20% ethanol consumption or water consumption on mean plasma corticosterone levels, and (f) correlations between
plasma corticosterone levels and 4-h 20% ethanol consumption, in C57BL/6J animals (n¼ 15 per group). Data represent mean±SEM, and are normalized
for body weight. *po0.05 vs vehicle-treated group determined by Bonferroni post hoc analyses.
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The current results indicate that central CRFR signaling
modulates binge-like ethanol drinking in mice, and show
that both CRF1R and CRF2R are involved. Furthermore, the
present results are not consistent with a role for HPA axis
signaling in the modulation of binge-like drinking, and
show that the effects of CRF1R antagonism on binge-like
drinking do not require normal HPA axis function. These
conclusions are based on the following observations: (1)
i.c.v. administration of a nonselective CRFR antagonist
attenuated binge-like drinking, (2) i.c.v. infusion of the
CRF2R agonist, Ucn3, dose-dependently reduced binge-like
drinking, (3) manipulation of the HPA axis independent of
CRF antagonism (ie, blockade of glucocorticoid receptor or
inhibition of corticosterone synthesis with administration
of metyrapone or ADX) failed to selectively protect against
binge-like ethanol consumption, (4) binge-like ethanol
drinking did not influence plasma corticosterone levels in
mice, and (5) pretreatment with CP, a CRF1R antagonist,
attenuated ethanol consumption to a similar degree in both
ADX- and SHAM-treated mice, showing that CP-induced
reduction of binge-like ethanol drinking does not require
normal HPA axis signaling. These observations provide
novel insights into the mechanisms by which CRFR
signaling modulates binge-like drinking behavior in
C57BL/6J mice.
The observation that central CRFR signaling modulates
binge-like ethanol consumption complements the current
literature indicating an integral role for central CRFRs in
the modulation of neurobiological responses to ethanol. For
example, the central administration of nonselective CRFR
antagonists has previously been shown to attenuate
increased ethanol consumption (Finn et al, 2007; Funk
et al, 2006; Valdez et al, 2002) and relapse of ethanol-
seeking behavior (Le et al, 2002; Liu and Weiss, 2002) in
ethanol-dependent rodents. In addition, there are examples
of a role for CRFR signaling in non-dependent ethanol
drinking, as CRF1R antagonists have been shown to
attenuate deprivation-induced drinking in mice (Sparta
et al, 2009), stress-induced drinking in rats and mice
(Lowery et al, 2008; Overstreet et al, 2007), and the
acquisition of ethanol consumption in isolation-reared rats
(Lodge and Lawrence, 2003). It should be noted that a
recent report failed to find an effect of a CRF1R antagonist
on binge-like drinking using a rat model (Ji et al, 2008).
However, in addition to species differences, Ji et al (2008)
used a sweetened alcohol solution to induce increased
ethanol drinking in their paradigm.
Central infusion of the nonselective CRFR antagonist
a-helical CRF did not attenuate ethanol consumption in a
dose-dependent manner in this report, a finding that is in
agreement with a previous observation of biphasic effects of
a-helical CRF on reinstatement to heroin-seeking behavior,
where lower doses (eg, 3mg) attenuated reinstatement and
higher doses (eg, 10 mg) had no effect on behavior (Shaham
et al, 1997). Similar biphasic effects of this drug have also
been noted for anxiety-like behavior induced by ethanol
withdrawal (Menzaghi et al, 1994; Rassnick et al, 1993) or
stress (Heinrichs et al, 1994). Such biphasic effects of
Figure 4 (a) Effects of adrenalectomy on mean 2-h 20% ethanol consumption by C57BL/6J animals during the first 3 days of the DID procedure
(n¼ 24–40 per group). Effects of CP on (b) mean 4-h 20% ethanol consumption, and (c) blood–ethanol concentrations by ADX or SHAM C57BL/6J
animals on day 4 (n¼ 8–14 per group). (d) Effects of adrenalectomy on mean 2-h 3% sucrose consumption by C57BL/6J animals (n¼ 23–40). Data
represent mean±SEM, and are normalized for body weight. *po0.05 vs vehicle-treated group, + po0.05 vs SHAM group, determined by Bonferroni post
hoc analyses.
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a-helical CRF on behavior may be due in part to this drug’s
actions as a partial agonist at the CRF1R with increasing
doses (Smart et al, 1999). As central administration of
CRF promotes hyperactivity and stereotyped behavior
(Matsuzaki et al, 1989; Song et al, 1995, 1997; Terawaki
et al, 2004; Veldhuis and De Wied, 1984), it is possible that
hyperactivity in mice that received the 10 mg dose of
a-helical CRF caused ethanol spillage, which would account
for low BECs in this group despite what appeared to be high
levels of ethanol intake. Importantly, here we provide novel
evidence that central CRF2R signaling also modulates binge-
like ethanol drinking, as central infusion of the highly
selective CRF2R agonist Ucn3 attenuated binge-like ethanol
consumption in C57BL/6J mice. It should be noted that
central CRFR signaling appears to selectively modulate
binge-like ethanol drinking, rather than consumption of
other reinforcing/caloric substances in general, as doses of
centrally infused drugs (ie, 1 mg of a-helical CRF, and 0.1
and 0.5 mg of Ucn3) that effectively reduced 20% ethanol
consumption did not have effects on 10% sucrose
consumption.
The present results with central infusion of the CRF2R
agonist, Ucn3, are consistent with those obtained with the
CRF1R and CRF2R agonist, Ucn1, which, when delivered
into the lateral septum (an area densely populated with
CRF2R), also blunted binge-like drinking in mice (Ryabinin
et al, 2008). To date, blockade of the CRF1R with CP-154,526
(here and Sparta et al, 2008), activation of CRF1R and/or
CRF2R in the lateral septum with site-directed infusion of
Ucn1 (Ryabinin et al, 2008), and activation of CRF2R with
Ucn3 (in this report) are all treatments that protect against
binge-like ethanol drinking in C57BL/6J mice. Taken
together, the most parsimonious mechanism based on the
current data is one in which CRF1R activation promotes,
and CRF2R activation blunts, binge-like ethanol drinking. It
will be important to determine which endogenous ligands
(CRF and the Ucn peptides) and which brain regions (in
addition to the lateral septum) are involved.
Corticotropin-releasing factor activity is known to have
significant effects on HPA axis signaling as well as
extrahypothalamic brain systems, though its role in
ethanol-related behaviors appear to be primarily mediated
extrahypothalamically (Koob, 2003, 2008). The current
results obtained using various experimental manipulations
of the HPA axis suggest that binge-like ethanol drinking by
C57BL/6J is not likely modulated by HPA axis signaling.
First, blunted HPA axis signaling attributed to adrenalect-
omy or pretreatment with metyrapone, a corticosterone
synthesis inhibitor, nonselectively reduced both ethanol and
sucrose consumption. These results are in agreement with
previous studies indicating that adrenalectomy reduces
both voluntary ethanol (Fahlke et al, 1995) and sucrose
consumption (Seidenstadt and Eaton, 1978). Likewise,
metyrapone has also been shown to reduce ethanol
consumption at similar doses (Fahlke et al, 1994; O’Call-
aghan et al, 2005), and corticosterone signaling has been
implicated in the self-administration of other drugs of
abuse, including cocaine (Goeders and Guerin, 1996, 2008)
and amphetamine (Piazza et al, 1991). Taken together, these
data suggest that HPA axis signaling may generally
modulate the self-administration of substances with
reinforcing properties.
The second point suggesting that HPA axis signaling is
not necessary for the expression of binge-like ethanol
drinking is the observation that pretreatment with mife-
pristone, a glucocorticoid receptor antagonist, did not alter
binge-like ethanol consumption at any of the doses tested.
Although one investigation did report dose-dependent
attenuation of 1-h ethanol consumption following periph-
eral pretreatment with 1–20 mg/kg doses of mifepristone
(Koenig and Olive, 2004), several other investigations, in
addition to this report, have found that the blockade of
glucocorticoid receptors does not alter ethanol consump-
tion (Fahlke et al, 1995, 1996; O’Callaghan et al, 2005; Yang
et al, 2008). Although it has been reported that mifepristone
is rapidly metabolized in several species, including rats
(Peeters et al, 2004), it is unlikely that this factor accounts
for the observed lack of effect on binge-like ethanol
drinking because hourly measurements of binge-like
ethanol drinking also failed to show an effect of mifepris-
tone. On the basis of the study by Koenig and Olive (2004),
it is possible that mifepristone would have effectively
reduced binge-like ethanol consumption had a lower dose
range been used. However, this is unlikely as attenuation of
ethanol consumption was greatest at the highest dose tested
(20 mg/kg) (Koenig and Olive, 2004), and yet no alterations
in ethanol consumption were observed after administration
of a 25 mg/kg dose of mifepristone in this study.
Furthermore, the literature indicates that mifepristone is
most efficacious at high doses when administered periph-
erally as this compound does not readily cross the blood–
brain barrier (Peeters et al, 2004). Although the factors
that contribute to the inconsistencies between the Koenig
and Olive, (2004) study and this report are not clear, one
straightforward interpretation is that glucocorticoid
receptor signaling modulates limited access ethanol con-
sumption by rats, but not binge-like ethanol drinking in
C57BL/6J mice.
The third point suggesting that HPA axis signaling does
not modulate binge-like drinking is the observation that
binge-like ethanol intake did not alter circulating levels of
corticosterone in C57BL/6J mice relative to mice drinking
water. As corticosterone is often used as a marker of HPA
axis activity (Richardson et al, 2008), these results suggest
that binge-like ethanol consumption is not driven by
heightened HPA axis activity. Although 4-h of binge-like
ethanol drinking did not alter plasma corticosterone levels
in this study, some reports have shown robust increases in
circulating corticosterone following ethanol administration
through multiple routes, including intravenous (Richardson
et al, 2008), intragastric (Lee and Rivier, 1997; Ogilvie et al,
1997), and i.p. (Ogilvie et al, 1997) ingestion in the form of
ethanol diet (Ogilvie et al, 1997), and self-administration
(Richardson et al, 2008). Although these results suggest that
ethanol can stimulate HPA axis activity, such activity
appears to be sensitive to the time of day. Thus, the effects
of ethanol administration on corticosterone levels have
primarily been observed during the animals’ light cycle,
when basal corticosterone levels are typically low relative to
corticosterone levels during the dark cycle (Loh et al, 2008).
Although one recent report describes ethanol-induced
increases in plasma corticosterone during the dark cycle
(Richardson et al, 2008), it is difficult to draw direct
comparisons with this study as different species (rats vs
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mice) and routes of ethanol administration (intravenous vs
ethanol drinking) were used.
It should be noted that binge-like ethanol intake may
have triggered an increase in plasma corticosterone levels,
but such increases may have been transient and thus missed
at the sampling time used (4 h after the initiation of ethanol
consumption on the fourth day of ethanol access). For
example, it is possible that ethanol-induced increases of
plasma corticosterone occur transiently toward the begin-
ning of ethanol consumption and thus returned to baseline
levels before the blood samples were collected 4 h after
ethanol consumption began. It is also possible that mice
develop tolerance to ethanol-induced increases of plasma
corticosterone levels, and that such tolerance may have been
complete by the fourth day of ethanol access. Nonetheless,
the converging data set suggest that normal HPA axis
signaling is not necessary for the expression of binge-like
drinking in C57BL/6J mice, and as noted above, CRF1R
blockade appears to blunt binge-like drinking without
involving the HPA axis.
According to the allostasis model of ethanol dependence
(Koob and Kreek, 2007; Koob, 2003, 2008), repeated
exposure to, and withdrawal from, high amounts of ethanol
lead to functionally significant neuroadaptations that
translate into persistent increases of anxiety, craving for
ethanol, and ultimately excessive ethanol intake. Some of
the most well-characterized neuroadaptations resulting
from a history of ethanol exposure occur within the CRF
system of the extended amygdala (Ciccocioppo et al, 2006;
Funk et al, 2006; Merlo Pich et al, 1995; Olive et al, 2002;
Zorrilla et al, 2001). Evidence includes increased amygdalar
CRF immunoreactivity (Funk et al, 2006; Pich et al, 1995;
Zorrilla et al, 2001), increased dialysate CRF levels (Olive
et al, 2002), and increased amygdalar expression of the
CRF1R (Sommer et al, 2008), following experimental
induction of ethanol dependence. Therefore, imbalances in
CRF signaling characterize the neurobiology of ethanol
dependence. Our results provide evidence of a role for
CRFR signaling in binge-like ethanol consumption, a
behavior that is proposed to be a gateway to ethanol
dependence (Koob, 2003). Importantly, the current data,
and work that assessed deprivation-induced increases of
ethanol consumption (Sparta et al, 2009), suggest that CRFR
signaling is engaged early in the transition to ethanol
dependence. An interesting possibility is that repeated
ethanol binges lead to the development of ethanol
dependence by inducing significant neuroadaptations in
the CRF and/or Ucn systems. Viewed this way, repeated
activation of the central CRF system with repeated episodes
of binge drinking progressively leads to neuroadaptive
(allostatic) alterations in CRF receptor signaling, which
culminates in ethanol dependence.
In conclusion, this study provides novel insights into the
mechanisms by which CRFR signaling modulates binge-like
ethanol consumption. The present findings, in tandem with
previous reports (Sparta et al, 2008; Ryabinin et al, 2008),
suggest that central CRFR signaling modulates excessive
binge-like ethanol intake without influencing ethanol intake
in mice drinking moderate amounts of ethanol and which
achieve modest BECs. In addition, both CRF1R and CRF2R
appear to be involved. On the other hand, HPA axis
signaling does not appear to be a mechanism that is
necessary for (or specific to) the expression of binge-like
ethanol drinking in C57BL/6J mice, or for CRF1R antagon-
ism-induced blunting of binge-like ethanol intake. Future
research is needed to identify the brain regions in which
CRFR signaling is recruited during binge-like ethanol
consumption, and to determine the roles of CRF and the
Ucn family of peptides in modulating this behavior. Finally,
the present observations reinforce and expand the current
literature by showing that CRF1R and CRF2R signaling are
recruited during the early phases of excessive ethanol
ingestion. A recent study reported genetic linkage between
polymorphisms of the corticotropin releasing hormone 1
receptor gene and binge drinking in humans (Treutlein
et al, 2006). An exciting possibility is that CRF1R
antagonists and CRF2R agonists, in addition to having
potential therapeutic value in treating ethanol dependence,
may also be attractive targets for treating binge drinking
and preventing the transition to dependence in humans.
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